Related Experiment Video
Updated: Aug 8, 2026
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients
Fermina M Mazzella1, David Smith, Paul Horn
1Department of Pathology and Laboratory Medicine, Medical College of Georgia, Augusta, USA. mazzella@uchc.edu
Abstract:
Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast-predominant) and disease (M6b, pronormoblast-predominant). M6c (mixed myeloblast/pronormoblast) has also been described. However, MDS is still defined according to the percentage of myeloblasts (% myeloblasts) without including the pronormoblast count. A 20-year retrospective study was performed to identify cases demonstrating >or=50% erythrocytic component and <30% calculated blasts (FAB exclusion criteria) without underlying cause (96 cases). Pronormoblast and myeloblast counts and other variables were analyzed as possible explanatory variables of the variations in survival. Considered alone, increasing % myeloblasts and/or percentage of pronormoblasts (% pronormoblasts) were significant predictors of decreasing survival. When all variables were considered as a multivariate group, the best fitting statistical model for predicting survival was a function of age, % pronormoblasts, IPSS cytopenias, platelet count, and percentage erythrocytic component. Of these, % pronormoblasts was by far the most significant. Nonappearance of % myeloblasts in this model is indicative of high correlations of this count with other variables.
Insights
This study reveals that pronormoblast percentage is a crucial factor in predicting survival for acute erythroleukemia, more so than myeloblasts. Understanding these factors improves leukemia classification and patient outcomes.
Area of Science:
- Hematology
- Oncology
- Clinical Pathology
Background:
- Acute erythroleukemia classification includes DiGuglielmo's syndrome (M6a, M6b, M6c).
- Myelodysplastic syndromes (MDS) are currently defined by myeloblast percentage, excluding pronormoblasts.
- A need exists to refine prognostic markers in erythroid-predominant leukemias.
Purpose of the Study:
- To investigate the prognostic significance of pronormoblasts and myeloblasts in acute erythroleukemia.
- To identify key variables predicting survival in erythroid-predominant leukemias.
- To evaluate the current MDS classification criteria in relation to erythroleukemia prognosis.
Main Methods:
- Retrospective analysis of 96 cases meeting erythrocytic component and blast count criteria.
- Analysis of pronormoblast and myeloblast counts, age, cytopenias, and platelet count.
- Multivariate statistical modeling to determine predictors of survival.
Main Results:
- Increasing percentages of both myeloblasts and pronormoblasts independently predicted decreased survival.
- The most significant predictor of survival in the multivariate model was the percentage of pronormoblasts.
- Age, IPSS cytopenias, platelet count, and erythrocytic component also contributed to the survival model.
- Myeloblast percentage was highly correlated with other variables and not independently significant in the final model.
Conclusions:
- Pronormoblast percentage is a critical prognostic factor in acute erythroleukemia, surpassing myeloblast percentage.
- Current MDS classification may need revision to incorporate pronormoblast counts for improved prognostic accuracy.
- Accurate assessment of erythroid precursors is essential for refining leukemia diagnosis and predicting patient survival.
More Related Videos
06:39Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:14Erythropoiesis